Arch Resources (ARCH) Competitors

Cerevel Therapeutics (NASDAQ:CERE) and Arch Resources (NYSE:ARCH) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, community ranking, risk, valuation, earnings and dividends.

Which has more volatility and risk, CERE or ARCH?

Cerevel Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Arch Resources has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500.

Does the media refer more to CERE or ARCH?

In the previous week, Cerevel Therapeutics and Cerevel Therapeutics both had 5 articles in the media. Cerevel Therapeutics' average media sentiment score of 1.24 beat Arch Resources' score of 1.13 indicating that Arch Resources is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerevel Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arch Resources	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is CERE or ARCH more profitable?

Arch Resources has a net margin of 10.89% compared to Arch Resources' net margin of 0.00%. Cerevel Therapeutics' return on equity of 22.32% beat Arch Resources' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerevel Therapeutics	N/A	-98.94%	-45.07%
Arch Resources	10.89%	22.32%	13.31%

Do institutionals and insiders believe in CERE or ARCH?

87.7% of Cerevel Therapeutics shares are owned by institutional investors. Comparatively, 88.1% of Arch Resources shares are owned by institutional investors. 5.1% of Cerevel Therapeutics shares are owned by insiders. Comparatively, 5.9% of Arch Resources shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has higher earnings and valuation, CERE or ARCH?

Arch Resources has higher revenue and earnings than Cerevel Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerevel Therapeutics	N/A	N/A	-$432.84M	N/A	N/A
Arch Resources	$3.15B	0.98	$464.04M	$17.00	10.00

Do analysts prefer CERE or ARCH?

Cerevel Therapeutics presently has a consensus target price of $42.67, suggesting a potential upside of 4.37%. Arch Resources has a consensus target price of $177.00, suggesting a potential upside of 4.11%. Given Arch Resources' higher possible upside, analysts plainly believe Cerevel Therapeutics is more favorable than Arch Resources.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerevel Therapeutics	0 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.11
Arch Resources	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the MarketBeat Community believe in CERE or ARCH?

Arch Resources received 373 more outperform votes than Cerevel Therapeutics when rated by MarketBeat users. However, 66.52% of users gave Cerevel Therapeutics an outperform vote while only 61.68% of users gave Arch Resources an outperform vote.

Company	Underperform	Outperform
Cerevel Therapeutics	Outperform Votes 155 66.52%	Underperform Votes 78 33.48%
Arch Resources	Outperform Votes 528 61.68%	Underperform Votes 328 38.32%

Summary

Arch Resources beats Cerevel Therapeutics on 11 of the 14 factors compared between the two stocks.